NEW YORK, NY / ACCESSWIRE / September 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Live Ventures Incorporated (NASDAQ:LIVE)
Class Period: December 28, 2016 - August 3, 2021
Lead Plaintiff Deadline: October 12, 2021
Throughout the class period, Live Ventures Incorporated allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) Live's earnings per share for FY 2016 was actually only $6.33 per share; (2) the Company used an artificially low share count to boost the earnings per share by 40%; (3) Live had overstated pretax income for fiscal 2016 by 20% by including $915,500 of "other income" related to certain amendments that were not negotiated until after the close of the fiscal year; (4) Live's acquisition of ApplianceSmart did not close during first quarter 2017; (5) using December 30, 2017 as the "acquisition date" and recognizing income therefrom did not conform to generally accepted accounting principles; (6) by falsely stating that the acquisition closed during the quarter, Live recognized bargain purchase gain, which enabled the Company to report positive net income in what would otherwise have been an unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, Live's CEO received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in LIVE: https://www.kleinstocklaw.com/pslra-1/live-ventures-incorporated-loss-submission-form?id=19483&from=1
Sesen Bio, Inc. (NASDAQ:SESN)
Class Period: December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline: October 18, 2021
The SESN lawsuit alleges that throughout the class period, Sesen Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in SESN: https://www.kleinstocklaw.com/pslra-1/sesen-bio-inc-loss-submission-form?id=19483&from=1
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
Class Period: December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline: November 1, 2021
The complaint alleges that during the class period Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in SPPI: https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=19483&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm